ライフサイエンスコーパス: topoisomerase IV

1 the target proteins, GyrA (gyrase) and ParC (topoisomerase IV).

2 1215 allele, encoding one of the subunits of topoisomerase IV.

3 specifically target bacterial DNA gyrase and topoisomerase IV.

4 cted a fusion protein of the two subunits of topoisomerase IV.

5 hose formed with either the wild type Gyr or topoisomerase IV.

6 formed with Gyr (A59), the wild type Gyr, or topoisomerase IV.

7 difference in the drug interaction domain on topoisomerase IV.

8 ates of DNA religation mediated by S. aureus topoisomerase IV.

9 pping in parC, one of the two genes encoding topoisomerase IV.

10 replication via inhibition of DNA gyrase and topoisomerase IV.

11 roquinolone that targets both DNA gyrase and topoisomerase IV.

12 ainst a range of gyrase variants and E. coli topoisomerase IV.

13 dual inhibition of bacterial DNA gyrase and topoisomerase IV.

14 t does not require the catalytic activity of topoisomerase IV.

15 indicating that the proteins are subunits of topoisomerase IV.

16 e ATP binding pockets of both DNA gyrase and topoisomerase IV.

17 e DNA helicase might overcome DNA gyrase and topoisomerase IV.

18 leaved complex for N. gonorrhoeae gyrase and topoisomerase IV.

19 to unlink precatenated sister chromosomes by Topoisomerase IV.

20 bind to the catalytic site of DNA gyrase and topoisomerase IV.

21 acidic residue in the A subunit of gyrase or topoisomerase IV.

22 egion encompassing the parEC operon encoding topoisomerase IV.

23 eta (TOP2B), and two in bacteria, gyrase and topoisomerase IV.

24 he DNA cleavage reaction of Escherichia coli topoisomerase IV.

25 karyotic topoisomerases I and II, and E.coli topoisomerase IV.

26 Surprisingly, we find that the CTD of the topoisomerase IV A subunit, which shares limited sequenc

27 pathogens, inhibition of both DNA gyrase and topoisomerase IV, a low frequency of resistance, a favor

28 Topoisomerase IV, a prokaryotic type II topoisomerase, c

29 Protection of topoisomerase IV, a secondary target of quinolone action

30 In Escherichia coli, topoisomerase IV, a type II topoisomerase, mediates the

31 In bacteria, DNA gyrase and topoisomerase IV act ahead of the fork to keep DNA under

32 We demonstrated that DNA topoisomerase IV, acting in concert with topoisomerase I

33 ing as a means of globally regulating MukBEF-topoisomerase IV activity in space and time.

34 In addition, the majority of topoisomerase IV activity in synchronized cell populatio

35 These observations suggest that topoisomerase IV activity in vivo might be dependent on

36 intermediates of DNA replication, even when topoisomerase IV activity is removed.

37 When topoisomerase IV activity was blocked, either with a dru

38 Following inhibition of gyrase, topoisomerase IV alone relaxed plasmid DNA to a final su

39 Topoisomerase IV also was able to distinguish DNA geomet

40 bunit of the cellular chromosomal decatenase topoisomerase IV, an interaction that is required for pr

41 They are inhibitors of bacterial gyrase and topoisomerase IV and demonstrate clinically useful antib

42 by 34, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against cip

43 e nonsupercoiling class, including bacterial topoisomerase IV and eukaryotic topoisomerase II enzymes

44 The hybrids inhibited the FQ targets, topoisomerase IV and gyrase, with potencies similar to n

45 ping the DNA cleavage complexes of bacterial topoisomerase IV and gyrase.

46 with all the subunits of both DNA gyrase and topoisomerase IV and has measurable effects on their act

47 was attributable to an increased demand for topoisomerase IV and is unlikely to define a new role fo

48 ng sites located on bacterial DNA gyrase and topoisomerase IV and not utilized by marketed antibiotic

49 h exhibited micromolar inhibition of E. coli topoisomerase IV and of Staphylococcus aureus homologues

50 s between clinically relevant quinolones and topoisomerase IV and provide a likely mechanism for the

51 oroquinolone inhibitor of DNA gyrase, and to topoisomerase IV and were almost completely resistant to

52 olates contained mutations in both parC (DNA topoisomerase IV) and gyrA (DNA gyrase), which were show

53 inhibitory activities against DNA gyrase and topoisomerase IV, and (c) no inhibitory activity against

54 it the type 2 topoisomerases, DNA gyrase and topoisomerase IV, and can cleave DNA at sites where thes

55 Although topoisomerase IV appears to be the primary cytotoxic tar

56 Bacterial DNA gyrase and topoisomerase IV are essential enzymes that control the

57 Bacterial DNA gyrase and topoisomerase IV are well-characterized clinically valid

58 erial type II topoisomerases (DNA gyrase and topoisomerase IV) are of interest for the development of

59 two-hybrid screen using the ParE subunit of topoisomerase IV as bait.

60 Our results demonstrate that topoisomerase IV at increased expression is necessary an

61 g the subunits of the chromosomal decatenase topoisomerase IV) at restrictive temperatures by high-co

62 relaxation of negatively supercoiled DNA by topoisomerase IV becomes distributive, whereas relaxatio

63 ion of gyrase ahead of replication forks and topoisomerase IV behind them causes fluoroquinolone-medi

64 E-ParC55)2 dimer of Streptococcus pneumoniae topoisomerase IV bound to two DNA molecules: a closed DN

65 onorrhoeae type II topoisomerases gyrase and topoisomerase IV by AZD0914 (AZD0914 will be henceforth

66 iments that analyzed individual steps of the topoisomerase IV catalytic cycle were undertaken to addr

67 d that specific interactions between dif and topoisomerase IV caused cleavage at that site.

68 Removal of both topoisomerase I and topoisomerase IV caused the DNA to become hyper-negative

69 ne action in bacteria and a new way to study topoisomerase IV-chromosome interactions.

70 seq, we detected Escherichia coli gyrase and topoisomerase IV cleavage complexes at hundreds of sites

71 ution view of the distribution of gyrase and topoisomerase IV cleavage complexes on DNA.

72 Based on these findings, we propose that topoisomerase IV cleaves DNA using a two-metal-ion mecha

73 These findings suggest that the MukB-topoisomerase IV complex may provide a scaffold for DNA

74 in the gyrA and parC genes of the DNA gyrase/topoisomerase IV complex that occurred in the presence o

75 DNA gyrase and topoisomerase IV control bacterial DNA topology by break

76 Bacterial DNA gyrase and topoisomerase IV control the topological state of DNA du

77 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-p

78 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent antibacterial activity

79 are potent inhibitors of both DNA gyrase and topoisomerase IV, displaying antibacterial activities ag

80 the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form

81 y is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that can arrest the

82 caffold against the N-terminal domain of the topoisomerase IV E subunit from Escherichia coli (eParE)

83 ses, DNA gyrase encoded by gyrB and gyrA and topoisomerase IV encoded by parE and parC.

84 bacterial condensin, and ParC, a subunit of topoisomerase IV, enhanced relaxation of negatively supe

85 ncodes a protein that does not interact with topoisomerase IV exhibit severe nucleoid decompaction le

86 tive feedback control of topoisomerase I and topoisomerase IV expression, which is typical of other b

87 Second, the preference of topoisomerase IV for catalyzing DNA decatenation over re

88 solubility, a 10-fold improved inhibition of topoisomerase IV from A. baumannii and P. aeruginosa, a

89 tion of Staphylococcus aureus DNA gyrase and topoisomerase IV from both bacteria.

90 he most balanced inhibitor of DNA gyrase and topoisomerase IV from both E. coli and S. aureus.

91 ibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-positive and a Gram-nega

92 st DNA gyrase from Staphylococcus aureus and topoisomerases IV from E. coli and S. aureus were determ

93 ed with negatively supercoiled) DNA, whereas topoisomerase IV generated similar levels with both subs

94 Although bacterial gyrase and topoisomerase IV have critical interactions with positiv

95 erial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drug

96 ics otherwise known to target DNA gyrase and topoisomerase IV in bacterial cells.

97 tions normally carried out by gyrase and DNA topoisomerase IV in other bacteria.

98 sistance mediated by decreased expression of topoisomerase IV in Staphylococcus aureus.

99 When fluoroquinolones bind to gyrase or topoisomerase IV in the presence of DNA, they alter prot

100 ng that the ParEC protein can substitute for topoisomerase IV in vivo.

101 Inhibition of topoisomerase IV in wild-type cells increased supercoili

102 et, where it directly bound to the bacterial topoisomerase IV, inhibiting its decatenation activity a

103 analog 49c was found to be a dual DNA gyrase-topoisomerase IV inhibitor, with broad antibacterial act

104 sed molecules that are potent DNA gyrase and topoisomerase IV inhibitors and display excellent antiba

105 Research into DNA gyrase and topoisomerase IV inhibitors has become a particular focu

106 ant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically.

107 ased optimization toward dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

108 ompounds toward balanced dual DNA gyrase and topoisomerase IV inhibitors with antibacterial activity.

109 ibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors.

110 s of bacterial topoisomerase (DNA gyrase and topoisomerase IV) inhibitors binding in the ATP domain a

111 he ATPase activity, that the ParC subunit of topoisomerase IV inhibits the MukB ATPase by preventing

112 ukB and the cellular chromosomal decatenase, topoisomerase IV interact and this interaction is requir

113 in MukB and the cellular decatenating enzyme topoisomerase IV interact.

114 We show here that the MukB-topoisomerase IV interaction stabilizes MukB on DNA, inc

115 Topoisomerase IV is a bacterial type II topoisomerase th

116 that a fusion protein of the two subunits of topoisomerase IV is a functional topoisomerase.

117 Topoisomerase IV is the primary cellular target for most

118 get the bacterial enzymes DNA gyrase and DNA topoisomerase IV, leading to bacterial cell death throug

119 Third, quinolones stimulate topoisomerase IV-mediated DNA cleavage both by increasin

120 rovafloxacin result from increased S. aureus topoisomerase IV-mediated DNA cleavage rather than inhib

121 Trovafloxacin induced topoisomerase IV-mediated DNA scission more rapidly than

122 that the particular substrate preferences of topoisomerase IV might be dictated in part by the functi

123 f topoisomerase III in temperature sensitive topoisomerase IV mutants in Escherichia coli results in

124 Dose-response experiments with two topoisomerase IV mutants that confer clinical resistance

125 When the test strain contained a preexisting topoisomerase IV mutation, which by itself conferred no

126 In these cells, ParC, one subunit of topoisomerase IV, no longer associated with the replicat

127 We conclude that topoisomerase IV, not gyrase, unknots DNA and that it is

128 ibacterial agents that attack DNA gyrase and topoisomerase IV on chromosomal DNA.

129 Using strains in which either DNA gyrase or topoisomerase IV, or both, were resistant to norfloxacin

130 FtsK is required for the localization of the topoisomerase IV ParC subunit to the replisome to facili

131 sociated MukBEF complexes also interact with topoisomerase IV (ParC(2)E(2)), so that their chromosome

132 get proteins-2 in DNA gyrase (GyrA) and 1 in topoisomerase IV (ParC), which occur in a stepwise manne

133 and the active domains of the E-subunits of topoisomerase IV (ParE) from a G(+) strain (Streptococcu

134 al inhibition of bacterial gyrase (GyrB) and topoisomerase IV (ParE), and it demonstrates efficacy in

135 es inhibit the overall catalytic activity of topoisomerase IV primarily by interfering with enzyme-AT

136 ally inactive and quinolone-resistant mutant topoisomerase IV proteins, nitrocellulose filter DNA bin

137 exes formed with either the wild type Gyr or topoisomerase IV remain stably bound.

138 iral arrangement of the DNA was required for topoisomerase IV stimulation because relaxation of posit

139 showed that selected compounds inhibited DNA topoisomerase IV, suggesting complex mechanisms of actio

140 equired the presence of either DNA gyrase or topoisomerase IV, suggesting that modulation of the topo

141 ulates intramolecular reactions catalyzed by topoisomerase IV, supercoiled DNA relaxation, and DNA kn

142 estigating the well-validated DNA gyrase and topoisomerase IV targets while preventing cross-resistan

143 rmation for further developing drugs against topoisomerase IV targets.

144 r weight, synthetic inhibitors of gyrase and topoisomerase IV that bind to the ATP sites are presente

145 regions of ParE, one of the two subunits of topoisomerase IV, that are involved in catalysis during

146 ated locus TcaR, DNA-binding protein II, and topoisomerase IV, that bound to the ica promoter.

147 As is the case with topoisomerase IV, the active cleavage and reunion activi

148 S81F/E85A) and GrlA(S81F) Bacillus anthracis topoisomerase IV, their sensitivity to quinolones and re

149 groups when reconstituted with ParC to form topoisomerase IV, those that elicited hyper-DNA cleavage

150 electively inhibits bacterial DNA gyrase and topoisomerase IV through a unique binding mode and has t

151 us anthracis and Escherichia coli gyrase and topoisomerase IV to relax and cleave positively supercoi

152 to evaluate contributions of gyrase and DNA topoisomerase IV to resistance.

153 s indicate that gyrase is better suited than topoisomerase IV to safely remove positive supercoils th

154 n topoisomerase IIalpha and Escherichia coli topoisomerase IV, to distinguish supercoil geometry duri

155 nventional type II topoisomerases, including topoisomerase IV, to DNA takes place at the catalytic do

156 timicrobial drugs target both DNA gyrase and topoisomerase IV (Topo IV) and convert these essential e

157 erial drugs target both DNA gyrase (Gyr) and topoisomerase IV (Topo IV) and form topoisomerase-quinol

158 n Escherichia coli, the MukB/E/F complex and topoisomerase IV (Topo IV) are both crucial players in t

159 DNA gyrase and topoisomerase IV (Topo IV) are cellular targets of quino

160 DNA gyrase and topoisomerase IV (Topo IV) are type II bacterial DNA top

161 We have studied the stimulation of topoisomerase IV (Topo IV) by the C-terminal AAA+ domain

162 bacterial type IIA topoisomerases gyrase and topoisomerase IV (Topo IV) catalyze DNA supercoiling and

163 DNA gyrase and topoisomerase IV (Topo IV) have distinct roles as unlink

164 ntified the parC and parE genes encoding DNA topoisomerase IV (Topo IV) in Caulobacter crescentus.

165 Topoisomerase IV (Topo IV) is a mediator of quinolone to

166 Escherichia coli topoisomerase IV (topo IV) is an essential enzyme that u

167 We showed recently that topoisomerase IV (topo IV) is the only important decaten

168 We found that both DNA gyrase and topoisomerase IV (topo IV) promote replication fork prog

169 DNA collision frequency for Escherichia coli topoisomerase IV (topo IV) that displays efficient non-e

170 ke component of the bacterial condensin, and topoisomerase IV (Topo IV), a type II topoisomerase that

171 In Escherichia coli, topoisomerase IV (Topo IV), encoded by parE and parC, is

172 ial type IIA topoisomerase, Escherichia coli topoisomerase IV (topo IV), using a combination of site-

173 of parE, encoding the ATP-binding subunit of topoisomerase IV (Topo IV), were purified and their acti

174 We have previously shown that DNA topoisomerase IV (topo IV), which is encoded by the parE

175 ParE and ParC proteins reconstituted to form topoisomerase IV (topo IV), which was highly proficient

176 t assay was employed to assess the effect of topoisomerase IV (Topo IV)-norfloxacin-DNA ternary compl

177 stigated the effects of abasic (AP) sites on topoisomerase IV (Topo IV).

178 the preferred substrate for Escherichia coli topoisomerase IV (topo IV).

179 ParE is the ATP-binding subunit of topoisomerase IV (Topo IV).

180 fore they undergo a complete decatenation by topoisomerase IV (Topo IV).

181 oils, a feature shared with Escherichia coli topoisomerase IV (Topo IV).

182 on was 50-60 bp for DNA gyrase and 40 bp for topoisomerase IV (Topo IV).

183 n with ori, and limiting the availability of topoisomerase IV (TopoIV) at ter.

184 pe II topoisomerases, such as DNA gyrase and topoisomerase IV (topoIV), are well-validated targets fo

185 Finally, topoisomerase IV unknotted DNA equally well when DNA rep

186 ch is strongly affected by DNA supercoiling, topoisomerase IV unknotted DNA independently of supercoi

187 s aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified.

188 The role of topoisomerase IV was revealed by two functional assays.

189 e distribution of ParE, the other subunit of topoisomerase IV, was unaffected.

190 religation reaction of Staphylococcus aureus topoisomerase IV were characterized.

191 eligation reactions of Staphylococcus aureus topoisomerase IV were characterized.

192 azole inhibitors of bacterial DNA gyrase and topoisomerase IV were developed.

193 ted directly that both topoisomerase III and topoisomerase IV were efficient at this task, whereas DN

194 f negatively supercoiled DNA and knotting by topoisomerase IV, which are intramolecular DNA rearrange

195 activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoi

196 positive supercoiling behind the fork where topoisomerase IV would also act to maintain replicating

197 We found that Escherichia coli topoisomerase IV, yeast topoisomerase II and human topoi